Skip to content

Adaptation of the STAIR-NT for First Responders

Adaptation of the STAIR-NT Intervention to Respond to Psychological Health Conditions for First Responders With a History of Traumatic Brain Injury

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07212140
Enrollment
80
Registered
2025-10-08
Start date
2026-11-01
Completion date
2027-06-01
Last updated
2026-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PTSD - Post Traumatic Stress Disorder, TBI-Traumatic Brain Injury

Keywords

PTSD, TBI, First responders, STAIR-NT, GMT

Brief summary

This study is a randomized controlled pilot examining the implementation of an adapted intervention, Skills Training in Affective and Interpersonal Regulation-Narrative Therapy (STAIR-NT), among a first responder population with a history of TBI and PTSD.

Detailed description

The primary objective of the study is to implement and evaluate the effectiveness of an evidence-based intervention, STAIR-NT, which will be adapted with Goal Management Training (GMT). A small-scale randomized control pilot will be conducted using the adapted intervention to examine implementation (i.e., feasibility, acceptability) and improvements in short-term PTSD, as well as secondary mental health outcomes (e.g., anxiety, and depression symptoms, substance misuse) among a first responder population with a history of TBI and PTSD.

Interventions

BEHAVIORALAdapted STAIR-NT

An adapted version of STAIR-NT that utilizes components from GMT in order to treat PTSD and TBI.

Sponsors

Florida State University
Lead SponsorOTHER
Invisible Wounds Project
CollaboratorUNKNOWN
United States Department of Defense
CollaboratorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Pilot randomized control trial with an intervention arm and a treatment-as-usual arm.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older * be a first responder within the state of Minnesota * have a history of a TBI * screen for PTSD.

Exclusion criteria

* Does not meet inclusion criteria.

Design outcomes

Primary

MeasureTime frameDescription
Change in Post-Traumatic Stress Disorder SymptomsBaseline, 4-6 weeks, 3 months, 6 monthsThe 20-item PTSD Checklist for DSM-5 (PCL-5) will be used to assess PTSD symptoms. All items are scored on a 5-point Likert scale ranging between 0 (not at all) and 4 (extremely).

Secondary

MeasureTime frameDescription
Change in Anxiety SymptomsBaseline, 4-6 weeks, 3 months, 6 monthsThe Generalized Anxiety Disorder Screener-7 (GAD-7) will be used to assess anxiety symptoms. The included items ask participants to indicate how frequently they experienced seven symptoms over the past two weeks, with provided response categories ranging between 0 (not at all) to 3 (nearly every day).
Change in Depression SymptomsBaseline, 4-6 weeks, 3 months, 6 monthsThe Patient Health Questionnarie-9 (PHQ-9) is an abbreviated version of the full PHQ focused on major depressive disorder and will be used to assess depression symptoms. Participants are asked to indicate how often they experienced nine different feelings over the past two weeks with possible response categories ranging between 0 (not at all) and 3 (nearly every day).
Change in Alcohol UseBaseline, 4-6 weeks, 3 months, 6 monthsThe Alcohol Use Disorders Identification Test (AUDIT) is a self-administered instrument that includes 10 screening questions tapping alcohol use and alcohol-related consequences in the past 12 months.
Change in Drug UseBaseline, 4-6 weeks, 3 months, 6 monthsThe Drug Abuse Screening Test (DAST-10) is a 10-item questionnaire tapping the use of drugs and related health effects and behaviors over the past 12 months.

Countries

United States

Contacts

CONTACTJoseph Schwartz, PhD
jaschwartz@fsu.edu850-644-7949
CONTACTTanya Renn, PhD
trenn@fsu.edu850-645-0903
PRINCIPAL_INVESTIGATORJoseph Schwartz, PhD

Florida State University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 26, 2026